Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.

[1]  K. Kliche,et al.  Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation , 2004, Journal of Cancer Research and Clinical Oncology.

[2]  J. Ferrara,et al.  The Pathophysiology of Acute Graft-versus-Host Disease , 2003, International journal of hematology.

[3]  J. Ferrara,et al.  Role of interleukin-18 in acute graft-vs-host disease. , 2003, The Journal of laboratory and clinical medicine.

[4]  J. Ferrara,et al.  Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. , 2003, Blood.

[5]  T. Brunner,et al.  IL-18-independent cytotoxic T lymphocyte activation and IFN-gamma production during experimental acute graft-versus-host disease. , 2002, International immunology.

[6]  M. Imamura.  Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation , 2002, International journal of hematology.

[7]  C. Dinarello,et al.  Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. , 2001, Journal of hematotherapy & stem cell research.

[8]  J. Ferrara,et al.  Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis , 2001, The Journal of experimental medicine.

[9]  H. Okamura,et al.  Fas ligand-induced caspase-1-dependent accumulation of interleukin-18 in mice with acute graft-versus-host disease. , 2001, Blood.

[10]  Jianmin Wang,et al.  [Roles of Cytokines in Acute Graft-Versus-Host Disease] , 2000, Zhongguo shi yan xue ye xue za zhi.

[11]  T. Masaoka,et al.  Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-γ in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation , 2000 .

[12]  H. Okamura,et al.  Elevated interleukin (IL)‐18 levels during acute graft‐versus‐host disease after allogeneic bone marrow transplantation , 2000, British journal of haematology.

[13]  D. Porter,et al.  Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. , 2000, Journal of hematotherapy & stem cell research.

[14]  R. Gress,et al.  Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma , 2000, Leukemia & lymphoma.

[15]  H. V. van Houwelingen,et al.  Serum cytokine levels after HLA-identical bone marrow transplantation. , 1998, Transplantation.

[16]  J. Gauldie,et al.  Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation , 1998, Bone Marrow Transplantation.

[17]  A. Zander,et al.  Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD , 1998, Bone Marrow Transplantation.

[18]  M. Asaka,et al.  Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. , 1997, Leukemia & lymphoma.

[19]  J. Ferrara,et al.  The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease , 1996, Stem cells.